| |
| [Comparative effectiveness of carbapenems and alternative antibiotics for the treatment of bacteraemia and/or urinary tract infectious disease by Enterobacteriaceae producing extended-spectrum β-lactamase] |
| Dong Ah Park, Jinnie Rhee, Na Rae Lee, Ji Jeong Park, Soo Kyung Son, Kyong Ran Peck, Su Yeun Moon, Eun-Jeong Joo, Jae-Ki Choi, Jae-Hoon Ko |
|
|
| |
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Dong Ah Park, Jinnie Rhee, Na Rae Lee, Ji Jeong Park, Soo Kyung Son, Kyong Ran Peck, Su Yeun Moon, Eun-Jeong Joo, Jae-Ki Choi, Jae-Hoon Ko. [Comparative effectiveness of carbapenems and alternative antibiotics for the treatment of bacteraemia and/or urinary tract infectious disease by Enterobacteriaceae producing extended-spectrum β-lactamase] Seoul: National Evidence-based Healthcare Collaborating Agency (NECA). NECA-A -16-001. 2016 Authors' conclusions This study systematically reviewed the recently published evidence to evaluate the clinical effectiveness of carbapenems and other alternative antibiotics in treating bacteremia and urinary tract infection caused by ESBL-producing Enterobacteriaceae and analyzed the comparative clinical outcomes of those therapies using multi-center data in Korea.
Although there was no clear evidence that superiority of carbapenem in empirical therapy, this study results suggest that carbapenem therapy is associated with a reduction of overall mortality when it is used as a definitive treatment in bacteremia caused by ESBL-producing Enterobacteriaceae, However, considering an increasing carbapenem resistance and non-inferiority of BL/BLIs use over carbapenems according to the study results, BL/BLIs can be used as alternatives for the treatment of patients with ESBL-positive Enterobacteriaceae bacteraemia.
In patients with ESBL-positive Enterobacteriaceae urinary tract infection, the role of carbapenem and other antibiotics should be further evaluated for empirical and definitive treatment.
Indexing Status Subject indexing assigned by CRD MeSH Anti-Bacterial Agents; Bacteremia; Carbapenems; Enterobacteriaceae; Humans; Urinary Tract Infections; beta-Lactamases Country of organisation South Korea English summary An English language summary is available. Address for correspondence National Evidence-based Healthcare Collaborating Agency (NECA), 7th floor Namsan Square, 173 Toegye-re, Jung-gu, Seoul, 100-705, South Korea
Email: hta_neca@neca.re.kr AccessionNumber 32016001008 Date abstract record published 22/09/2016 |
| |
|
|
